Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

医学 无容量 药代动力学 兴奋剂 抗体 药理学 效力 内科学 受体 癌症 肿瘤科 癌症研究 体外 免疫学 免疫疗法 化学 生物化学
作者
Howard A. Burris,Margaret K. Callahan,Anthony W. Tolcher,Shivaani Kummar,Gerald S. Falchook,Russell K. Pachynski,Scott S. Tykodi,Geoffrey T. Gibney,Tanguy Y. Seiwert,Justin F. Gainor,Patricia LoRusso,James Hilbert,Joshua F. Apgar,Fei Hua,John M. Burke,Manny Lazaro,Myles Clancy,Baoyu Ding,Elizabeth Trehu,Timothy A. Yap
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15_suppl): 3033-3033 被引量:28
标识
DOI:10.1200/jco.2017.35.15_suppl.3033
摘要

3033 Background: JTX-2011 is an agonist monoclonal antibody that targets ICOS, Inducible CO-Stimulator of T cells. A dual mechanism of action is intended to activate antigen-specific CD4 T effector cells and selectively deplete intratumoral T regulatory cells. JTX-2011 is equally potent across human, rodent, and non-human primate species. Methods: A quantitative systems pharmacology (QSP) model describing target binding by JTX-2011 and target mediated drug disposition in blood, tumor and non-tumor tissues was based on preclinical potency and non-linear PK data across species. The model was translated to predict PK and target engagement (TE) in humans to facilitate dose selection. The QSP model predicts > 95% TE for 21 days at the top planned dose. We present safety and actual/predicted PK from a Phase 1 study of JTX-2011 alone (Part A) and safety in combination with nivo (Part B). Results: 25 subjects have been dosed, 19 in 4 cohorts of JTX-2011 alone at .003, .01, .03, and .1 mg/kg IV q 21 days, and 6 in 2 cohorts of JTX-2011 .01 mg/kg and .03 mg/kg IV plus nivo 240 mg IV q21 days. Safety data from ≥ 1 cycle is available for 12 subjects in Part A (7 ≥ 3 cycles), and 3 in Part B (all ≥ 3 cycles). PK data is available for cycle 1 of Part A. Mean age (±SD) is 60 (±10.6). Mean prior systemic therapies is > 5 (range 1-11). Tumor types include endometrial, triple negative breast, melanoma, lung, pancreatic and colorectal cancers. No dose limiting toxicities have been reported. 3 Grade 3 adverse events (AEs) were reported in 2 Part A subjects: anemia and hypoxia (unrelated SAE) at .003 mg/kg and JTX-2011 related diarrhea at .1 mg/kg. Grade 1-2 AEs in ≥2 subjects are chills, pyrexia, neck pain, dizziness, and nausea. 5 subjects had JTX-2011 related Grade 1-2 infusion reactions up to 6 hours post infusion. Non-linear exposure increase was observed. While PK at lower doses is consistent with model predictions, AUC and t 1/2 at 0.03 and 0.1 mg/kg doses are higher than predicted, suggesting higher than predicted TE. Conclusions: JTX-2011 has been well tolerated up to 0.1 mg/kg and with nivo at .01 mg/kg IV q 21 days. Greater than linear exposure increase was observed and TE may be higher than QSP model prediction. Clinical trial information: NCT02904226.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
传奇3的应助被XiYang采纳,获得10
1秒前
pfliu完成签到,获得积分10
1秒前
2秒前
传统的无色完成签到,获得积分10
3秒前
SAKURA的应助被绒绒采纳,获得10
3秒前
无极微光的应助被陌路采纳,获得20
3秒前
3秒前
qq完成签到,获得积分10
3秒前
芽芽发布了新的文献求助100
4秒前
4秒前
叶牧尘的应助被樱桃小丸子采纳,获得10
4秒前
木木完成签到,获得积分10
5秒前
6秒前
现实的忆之完成签到 ,获得积分10
7秒前
王姿沣发布了新的文献求助10
7秒前
7秒前
7秒前
9秒前
上官若男的应助被流川枫采纳,获得10
9秒前
Lucas的应助被标致书易采纳,获得10
10秒前
10秒前
plj发布了新的文献求助10
10秒前
lc完成签到,获得积分10
10秒前
上官若男的应助被Lilililili采纳,获得30
11秒前
shiqiyuan发布了新的文献求助20
11秒前
山屿完成签到,获得积分10
12秒前
所所的应助被炙热代丝采纳,获得10
12秒前
丘比特的应助被赖以筠采纳,获得10
12秒前
13秒前
13秒前
义气语兰发布了新的文献求助10
13秒前
是我完成签到,获得积分10
13秒前
14秒前
14秒前
14秒前
14秒前
嵩易凯完成签到,获得积分10
14秒前
许伟洋完成签到,获得积分10
15秒前
LAN完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175556
求助须知:如何正确求助?哪些是违规求助? 9567240
关于积分的说明 21791502
捐赠科研通 7770174
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299